Takeda names GSK vaccine chief as COO; PharmAthene backs out of Theraclone merger;

> Takeda has named the president of GlaxoSmithKline's ($GSK) vaccine unit as its COO. News (sub. req.)

> PharmAthene ($PIP) is backing out of its proposed merger with Theraclone. Article

> Regulators in the Philippines have found counterfeit rabies vaccines. Item

> CMC Biologics is to manufacture a placental malaria vaccine. Release

> Sex and money are just two of several issues holding back HPV vaccines, research shows. Piece

> Only half of U.K. healthcare workers receive a routine flu vaccination. Article

> Korean CRO SillaJen has bought failed cancer vaccine Pexa-Vec. News

> The European CHMP has backed a two-dose regimen of GlaxoSmithKline's HPV vaccine. Item

> Immunicum has reported positive early-phase data for its therapeutic cancer vaccine. Release

Suggested Articles

GSK's Shingrix has generated blockbuster sales early in the launch, but there's a lot of remaining opportunity, an exec said at JPM.

Quickly after Merck's world-first Ebola vaccine approval in Europe, U.S. authorities licensed the shot.

In an effort to stop an Ebola outbreak that has claimed 2,200 lives at the Rwanda border, J&J is shipping 200,000 doses of its vaccine to the country.